Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease is a phase 3, randomised interventional study registered as NCT07750158 by Exelixis, with a registry enrolment figure of 600 participants, started 2026-08-25 and due to reach its primary completion in 2030-04-05. Interventions recorded: Zanzalintinib; Pembrolizumab (+) Berahyaluronidase alfa; Placebo. Conditions listed: Colorectal Cancer. Primary outcome: Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator; DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the Investigator. Colorectal eligibility wording from the registry: "* Histologically confirmed diagnosis of Stage II or III adenocarcinoma of colon or rectum". Sites: United States. No results are recorded here; the registry entry is the source.